Table 9.

Liver adverse events induced by approved monoclonal antibodies used for therapy.

Monoclonal Antibody	Liver Adverse Events
Adalimumab	Reactivates hepatitis B; liver failure
Ado-trastuzumab	Hepatotoxicity
Atezolizumab	Immune-mediated hepatitis
Avelumab	Immune-mediated hepatitis
Brentuximab vedotin	Hepatotoxicity
Catumaxomab	Hepatic disorders—hepatotoxicity
Cemiplimab-rwlc	Immune-mediated hepatitis
Certolizumab pegol	Reactivates hepatitis B
Daclizumab	Hepatic injury including autoimmune hepatitis
Dostarlimab-gxly	Immune-mediated hepatitis
Durvalumab	Immune-mediated hepatitis
Elotuzumab	Hepatotoxicity
Evolocumab	Hepatic impairment
Gemtuzumab ozogamicin	Hepatotoxicity including severe or fatal hepatic veno-occlusive disease
Golimumab	Reactivates hepatitis B
Infliximab	Hepatotoxicity
Inotuzumab ozogamicin	Hepatotoxicity including severe or fatal hepatic veno-occlusive disease
Natalizumab	Hepatotoxicity
Obinutuzumab	Reactivates hepatitis B
Ofatumumab	Reactivates hepatitis B
Polatuzumab vedotin-piiq	Hepatotoxicity
Rituximab	Reactivates hepatitis B
Vedolizumab	Possibility of liver injury suggested by elevated levels of transaminase and/or bilirubin